Menu
Recruiting NCT02455193

Neuronal Effects of Exercise in Schizophrenia

No phase Interventional Schizophrenia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Exercise, Diet.
Who it may be relevant to
Registry conditions: Schizophrenia. Basic parameters: 21 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

This study plans to learn more about how common drugs prescribed to individuals with schizophrenia contribute to weight gain, as well as how exercise and diet impact appetite and the brain's response to food. In this study, the investigators will be evaluating how participants' brains respond to food images as well as asking questions about their food preferences and intake and clinical symptoms. The investigators may also ask participants to complete an exercise or diet intervention to see how this changes brain responses or food preferences.

Interventions

  • Behavioral Exercise
  • Behavioral Diet

Primary outcome measures

  • Neuronal response to visual food cues [Time frame: 14 weeks]
  • Resting-state neuronal response [Time frame: 14 weeks]
Secondary outcome measures (3)
  • Appetite Rating on a visual analogue scale (VAS) [Time frame: 14 weeks]
  • Fasting leptin [Time frame: 14 weeks]
  • Fasting ghrelin [Time frame: 14 weeks]

Eligibility criteria

Inclusion criteria

  • Diagnosis of schizophrenia or schizoaffective disorder
  • Between 21 and 70 years of age
  • Currently prescribed either olanzapine, risperidone, clozapine, or haloperidol, OR not currently being treated with any neuroleptic medications
  • Weight stable within 5 percent for the last 6 months

Exclusion criteria

  • Pregnancy
  • Substance abuse
  • Significant endocrine/metabolic disease (e.g., uncontrolled hypertension, severe hypertriglyceridemia)
  • MRI-specific exclusion criteria (e.g., claustrophobia, metal in the body)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Other

Study locations

United States · 1 center
  • University of Colorado Anschutz Medical Campus — Aurora

Identifiers

NCT: NCT02455193 · 14-1282 · UL1TR001082 · R01MH102224

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗